Previous 10 | Next 10 |
Axogen continues posting double-digit growth in volumes against 2019 levels despite trauma, breast recon, and oral-maxillofacial procedures still well below pre-pandemic levels. COVID-19 infections are definitely a short-term risk and an impediment to sales and training efforts, but u...
The following slide deck was published by AxoGen, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: AxoGen, Inc. 2021 Q2 - Results - Earnings Call Presentation
The shares of medical device makers have come under pressure in morning hours after Texas Governor Greg Abbott encouraged the hospitals to consider postponing certain elective medical procedures to make room for rising COVID-19 patients in the state. The seven-day average of COVID-19 hospital...
Image source: The Motley Fool. AxoGen, inc (NASDAQ: AXGN) Q2 2021 Earnings Call Aug 4, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: AxoGen, inc (AXGN) Q2 2021 Earnings Call Transcript
AxoGen, Inc. (AXGN) Q2 2021 Earnings Conference Call August 04, 2021 4:30 PM ET Company Participants Pete Mariani – Executive Vice President and Chief Financial Officer Karen Zaderej – Chairman, Chief Executive Officer and President Conference Call Participants Brandon Folkes ...
AxoGen (NASDAQ:AXGN): Q2 Non-GAAP EPS of -$0.19 misses by $0.06; GAAP EPS of -$0.19 beats by $0.01. Revenue of $33.58M (+51.8% Y/Y) beats by $1.39M. Press Release For further details see: AxoGen EPS misses by $0.06, beats on revenue
ALACHUA, Fla. and TAMPA, Fla., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended June 3...
ALACHUA, Fla. and TAMPA, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president will pre...
ALACHUA, Fla. and TAMPA, Fla., July 19, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that John H. Johnson has been appointed to its Board of D...
ALACHUA, Fla. and TAMPA, Fla., July 14, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report second quarter 2021 financial results o...
News, Short Squeeze, Breakout and More Instantly...
ALACHUA and TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024, b...
2024-07-01 07:30:05 ET Raymond James analyst issues OUTPERFORM recommendation for AXGN on July 1, 2024 05:51AM ET. AXGN was trading at $7.24 at issue of the analyst recommendation. Historical Analyst Recommendations Latest 10 recommendations
ALACHUA, Fla. and TAMPA, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced making an inducement grant on July 1, 2024, under NASDAQ listing rule 5635(c)(4) in conn...